Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
PALI 
Palisade Bio Inc (PALI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/08/2025: PALI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11.67
1 Year Target Price $11.67
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -71.72% | Avg. Invested days 25 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 268.57M USD | Price to earnings Ratio - | 1Y Target Price 11.67 |
Price to earnings Ratio - | 1Y Target Price 11.67 | ||
Volume (30-day avg) 3 | Beta 1.64 | 52 Weeks Range 0.53 - 3.30 | Updated Date 12/8/2025 |
52 Weeks Range 0.53 - 3.30 | Updated Date 12/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.07 |
Earnings Date
Report Date 2025-11-10 | When - | Estimate -0.55 | Actual -0.38 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -87.81% | Return on Equity (TTM) -228.64% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 263551778 | Price to Sales(TTM) 14.03 |
Enterprise Value 263551778 | Price to Sales(TTM) 14.03 | ||
Enterprise Value to Revenue 234.89 | Enterprise Value to EBITDA 0.57 | Shares Outstanding 149003210 | Shares Floating 102195342 |
Shares Outstanding 149003210 | Shares Floating 102195342 | ||
Percent Insiders 0.01 | Percent Institutions 40.9 |
Upturn AI SWOT
Palisade Bio Inc
Company Overview
History and Background
Palisade Bio Inc. (formerly named Lumina Nano Inc.) was founded in 2005. The company, initially focused on nanotechnology, underwent a significant strategic shift to become a biopharmaceutical company. A key milestone was its reverse merger with Palisade Bio, Inc., a private biopharmaceutical company, in 2021, which led to its renaming and refocus on drug development. The company is dedicated to developing novel therapeutics for critical unmet medical needs, particularly in the areas of gastrointestinal diseases and oncology.
Core Business Areas
- Drug Development: Palisade Bio Inc. focuses on the development of innovative drug candidates. The company's primary efforts are directed towards its lead product candidate, PALISADE-1 (previously known as AN2690), a novel formulation of ursodeoxycholic acid (UDCA) designed to address various gastrointestinal disorders, including inflammatory bowel disease (IBD) and liver conditions. The company also explores other therapeutic areas, including oncology, with a focus on developing treatments with improved efficacy and safety profiles.
Leadership and Structure
Palisade Bio Inc. is led by a management team with experience in the biopharmaceutical industry. The organizational structure is typical of a clinical-stage biopharmaceutical company, emphasizing research and development, clinical operations, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- PALISADE-1 (Novel UDCA Formulation): PALISADE-1 is Palisade Bio Inc.'s lead drug candidate, aiming to treat inflammatory bowel disease (IBD) and potentially other gastrointestinal and liver conditions. The precise market share for this specific formulation is not yet established as it is in clinical development. Its primary competitors would be existing treatments for IBD, such as aminosalicylates (e.g., mesalamine), corticosteroids, immunomodulators (e.g., azathioprine, methotrexate), and biologics (e.g., infliximab, adalimumab). The market for IBD treatments is substantial and growing, with significant unmet needs for safer and more effective therapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by extensive research and development, long product development cycles, high regulatory hurdles, and significant investment. The market for treatments for gastrointestinal diseases, particularly inflammatory bowel disease, is substantial and driven by increasing prevalence and the demand for improved therapeutic options. The oncology market is also a major focus for innovation.
Positioning
Palisade Bio Inc. is positioned as a clinical-stage biopharmaceutical company focused on developing novel therapeutics for significant unmet medical needs. Its competitive advantage lies in its differentiated product candidate, PALISADE-1, which aims to offer improved efficacy and a favorable safety profile compared to existing treatments for IBD. The company seeks to leverage its scientific expertise and clinical development capabilities to bring its therapies to market.
Total Addressable Market (TAM)
The Total Addressable Market for inflammatory bowel disease treatments is estimated to be in the tens of billions of dollars globally and is projected to grow. Palisade Bio Inc.'s TAM for PALISADE-1, if successful, would encompass a significant portion of this market. The company is positioned to target specific patient populations within the IBD market that are inadequately served by current therapies.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (PALISADE-1) with potential for improved efficacy and safety.
- Focus on significant unmet medical needs in gastrointestinal diseases and oncology.
- Experienced management team with biopharmaceutical development background.
- Potential for strategic partnerships and collaborations.
Weaknesses
- Clinical-stage company with no approved products, leading to significant financial risk.
- Reliance on the success of a single lead product candidate.
- Limited financial resources compared to larger pharmaceutical companies.
- Dependence on external funding for continued development.
Opportunities
- Growing market for IBD and other gastrointestinal treatments.
- Advancements in drug delivery and formulation technologies.
- Potential for expansion into other therapeutic indications for PALISADE-1.
- Opportunities for licensing or acquisition by larger pharmaceutical companies.
- Emerging trends in personalized medicine and targeted therapies.
Threats
- Clinical trial failures or unexpected adverse events.
- Competition from existing and pipeline drugs.
- Regulatory hurdles and delays in drug approval.
- Changes in healthcare policy and reimbursement.
- Financing risks and inability to secure sufficient capital.
Competitors and Market Share
Key Competitors
- Takeda Pharmaceutical Company (TAK)
- AbbVie Inc. (ABBV)
- Janssen Biotech, Inc. (a Johnson & Johnson company) (JNJ)
- Eli Lilly and Company (LLY)
- Bristol Myers Squibb Company (BMY)
Competitive Landscape
Palisade Bio Inc. faces intense competition from established pharmaceutical giants with significant R&D budgets, extensive clinical development expertise, and broad commercialization infrastructure. Its key advantage lies in the potential for a novel mechanism of action and improved patient outcomes with PALISADE-1. However, it must overcome the challenges of proving clinical efficacy and safety, securing regulatory approval, and competing for market access and physician adoption against well-entrenched competitors with large market shares in IBD treatments.
Growth Trajectory and Initiatives
Historical Growth: Historically, Palisade Bio Inc.'s growth trajectory has been characterized by its transition from a nanotechnology focus to a biopharmaceutical development company. Its growth has been marked by strategic initiatives, capital raises to fund research, and progress through preclinical and clinical development stages. Revenue growth is not applicable at this pre-commercialization stage.
Future Projections: Future growth projections for Palisade Bio Inc. are heavily dependent on the successful clinical development and regulatory approval of its lead product candidate, PALISADE-1. Analyst estimates, if available, would likely focus on potential peak sales of PALISADE-1 in its target indications and the timeline for achieving commercialization. Any projections would carry significant inherent uncertainty.
Recent Initiatives: Recent initiatives have likely focused on advancing the clinical development of PALISADE-1, potentially through Phase 1, 2, or 3 trials, securing necessary regulatory approvals, and exploring strategic partnerships or collaborations to accelerate development and commercialization efforts.
Summary
Palisade Bio Inc. is a clinical-stage biopharmaceutical company with a focus on developing novel therapies for gastrointestinal diseases, notably inflammatory bowel disease with its lead candidate, PALISADE-1. The company's strength lies in its innovative drug candidate, but it faces significant risks due to its early stage of development and reliance on clinical success. Key challenges include intense competition from established players, regulatory hurdles, and the need for substantial funding. Successful progression through clinical trials and regulatory approval are critical for its future growth and survival.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings with the U.S. Securities and Exchange Commission (SEC)
- Industry reports on the biopharmaceutical market
- Financial news and analysis websites
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. The biopharmaceutical industry is highly speculative, and investing in companies like Palisade Bio Inc. carries significant risk. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Palisade Bio Inc
Exchange NASDAQ | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 2006-12-20 | CEO, CFO & Director Mr. J. D. Finley | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.palisadebio.com |
Full time employees 8 | Website https://www.palisadebio.com | ||
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.